Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • P-Richmond
    Member
    • Oct 2010
    • 13

    #1

    Coding/Noncoding and Synonymous/Nonsynonymous

    Has anyone calculated, for a given genome (S288c), what the % of the genome is coding vs noncoding? Also, has anyone calculated for the coding regions, the % of positions that when mutated cause a synonymous vs nonsynonymous SNP?

    If you can point me the right direction that would help.

    Cheers,
    Phil
  • DZhang
    Senior Member
    • Jun 2010
    • 177

    #2
    Phil,

    For the first few question, you need a simple script to do the calculation based on the gene annotation. Or for a specific genome, all the ORF sequences may already exist in fasta, which makes the task easier. As to your last question, you need to think it more carefully.

    Best regards,
    Douglas

    Comment

    • TiborNagy
      Senior Member
      • Mar 2010
      • 329

      #3
      I think it is very hard to calculate nonsynonymous SNPs, when some of the ORFs are overlap (source). Also very hard to calculate the coding vs noncoding percentages, because some of the ORFs are not verified (source).

      Comment

      • P-Richmond
        Member
        • Oct 2010
        • 13

        #4
        I've written a script that takes a reference fasta and a corresponding annotation gff3 and calculated for verified ORFs (non-overlapping) the synonymous vs. nonsynonymous percentages. For S288c, 6380 genes that fit into classical ORF descriptions (start, with stop in frame)--no spliced exons yet (sill working on that) the % of positions that have nonsynonymous potential is 74.9651%.

        This script should be generalizable and I can give it to those interested when its completed.

        -Phil

        Comment

        Latest Articles

        Collapse

        • SEQadmin2
          Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
          by SEQadmin2



          Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

          Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
          ...
          10-14-2026, 09:55 AM
        • SEQadmin2
          New Genomics Technologies Take Aim at Long-Standing Limits
          by SEQadmin2


          Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

          We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
          ...
          09-28-2026, 10:25 AM

        ad_right_rmr

        Collapse

        News

        Collapse

        Topics Statistics Last Post
        Started by SEQadmin2, 10-22-2026, 11:13 AM
        0 responses
        27 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 10-22-2026, 10:48 AM
        0 responses
        20 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 10-15-2026, 10:52 AM
        0 responses
        36 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 10-14-2026, 05:39 AM
        0 responses
        43 views
        0 reactions
        Last Post SEQadmin2  
        Working...